The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.e Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.h Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.k Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.s A mass or masses

I. Interstitial/parenchymal lung disease

I.u Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.w Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.z An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.aa Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ao Pulmonary infiltrates

I. Interstitial/parenchymal lung disease

I.at Amiodarone pulmonary toxicity - Amiodarone lung

I. Interstitial/parenchymal lung disease

I.ax Chronic pneumonitis

I. Interstitial/parenchymal lung disease

I.ay Unilateral interstitial lung disease

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.l Postoperative ARDS

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.d Cough (lone)

IV. Airway involvement

IV.r Airway pigmentation (black, bluish, petechial)

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.c Pleural thickening - Fibrothorax

V. Pleural and/or pericardial involvement

V.d Pleural/pericardial effusion, ANA positive (DI lupus)

V. Pleural and/or pericardial involvement

V.t The apical cap

VI. Pulmonary vasculopathy

VI.a Pulmonary embolism - Venous thrombosis/thromboembolism

VI. Pulmonary vasculopathy

VI.i Acute pulmonary hypertension

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ai Acute respiratory failure (hypoxemia, acidosis) from myxedema (-coma)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.q Systemic inflammatory response

XI. Miscellaneous

XI.c Pleuritic chest pain

XI. Miscellaneous

XI.f Bluish, pseudocyanotic skin discoloration

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.e Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.l Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.n Cardiovascular collapse - Cardiogenic shock - Hypotension

XII. Cardiovascular involvement / toxicity

XII.p QTc prolongation

XII. Cardiovascular involvement / toxicity

XII.t Torsades de pointe

XII. Cardiovascular involvement / toxicity

XII.af Coronary vasospasm - Vasospastic angina

XII. Cardiovascular involvement / toxicity

XII.au Heart failure (thyrotoxicosis-, thyroid storm-mediated)

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.g Path: Alveolar hemorrhage (see also IIIa)

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XV. Pathology

XV.i Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XV. Pathology

XV.j Path: Pulmonary fibrosis (UIP-pattern)

XV. Pathology

XV.k Path: Desquamative interstitial pneumonia (DIP-pattern)

XV. Pathology

XV.m Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern)

XV. Pathology

XV.o Path: Endogenous lipoid pneumonia (phospholipidosis)

XV. Pathology

XV.r Path: Smudged geographic necrosis

XV. Pathology

XV.ao Path: Pleuritis, pleural fibrosis

XV. Pathology

XV.bt Path: Histiocytic proliferation

XV. Pathology

XV.co Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

XV. Pathology

XV.dc Path: Acute eosinophilic pneumonia pattern (see also under XVIb)

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

XVI. Imaging

XVI.j Imaging: Wandering (migratory) pulmonary opacities

XVI. Imaging

XVI.n Imaging: Intralobular septal thickening - Crazy paving

XVI. Imaging

XVI.s Imaging: An area or areas of involvement with high attenuation numbers or metallic density

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.aa Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)

XVI. Imaging

XVI.ab Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ay Imaging: Asymmetrical, predominantly unilateral involvement

XVI. Imaging

XVI.az Imaging: Solitary pulmonary nodule

XVI. Imaging

XVI.bj Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)

XVI. Imaging

XVI.bq Imaging: A pattern consistent with pleuroparenchymal fibroelastosis

XVI. Imaging

XVI.bt Imaging: A subsolid lung nodule or nodules

XVI. Imaging

XVI.bx Imaging: Waxing and waning nodules

XVI. Imaging

XVI.ca Imaging: Disseminated patchy pulmonary opacities

XVII. Infections & related conditions

XVII.e Pneumocystis jiroveci pneumonia

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.b Eye catcher: Electron-dense area or areas of consolidation on unenhanced chest CT

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.j Eye-catcher: Avid lung uptake on 18F-PET-CT

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.k Eye-catcher: An electron-dense liver on unenhanced CT

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.p Eye-catcher: An electron-dense ('white') thyroid

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.b BAL: An excess proportion of neutrophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.c BAL: An excess proportion of eosinophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.e BAL: Stainable iron in macrophages

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.f BAL: Foamy macrophages

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.m BAL: A normal cell differential

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.p BAL: Lamellar bodies in AM on EM

XXVIII. Pulmonary physiology - PFTs

XXVIII.c Platypnea-orthodeoxia

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.e Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.j Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.m ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.n Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.u Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.v Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.aw Persistent reduction in diffusing capacity for CO upon resolution of the adverse effect

I. Interstitial/parenchymal lung disease

I.ax Chronic pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.u Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.m Coagulopathy

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.d Cough (lone)

IV. Airway involvement

IV.f Severe or catastrophic bronchospasm or asthma attack (can be fatal)

IV. Airway involvement

IV.k Bronchiectasis

IV. Airway involvement

IV.n Obstructive airway dysfunction (see also IVc, XVx)

IV. Airway involvement

IV.p Thermal, chemical or caustic airway injury

IV. Airway involvement

IV.q Reactive airway dysfunction syndrome (RADS)

IV. Airway involvement

IV.t Sptutum production - Bronchorrhea - 'Bronchitis'

IV. Airway involvement

IV.v Deterioration/exacerbation of preexisting asthma or COPD

IV. Airway involvement

IV.ad Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)

IV. Airway involvement

IV.al Sputum production - Bonchorrhea - ‘Bronchitis’

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.f Pneumothorax

VII. Mediastinal involvement

VII.a Lymphadenopathy (intrathoracic)

VII. Mediastinal involvement

VII.e Granulomatous mediastinal lymphadenopathy

VII. Mediastinal involvement

VII.h Pneumomediastinum

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.d Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.al Epiglottitis

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.an Facial/labial/buccal/oral/dental trauma

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.ap Airway foreign body

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.at Gross tracheal inflammation on endoscopy

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.aw Foreign body in the airway

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.bb Tracheitis including eosinophilic tracheal inflammation

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.bc Tracheal redness/inflammation on gross endoscopic examination

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.h Dyspnea, unexplained otherwise

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.af Seizures

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.q Systemic inflammatory response

X. Systemic/Distant conditions, syndromes and reactions

X.aq Relapse or flare of preexisting ulcerative colitis

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.r Death following exposure or poisoning

XI. Miscellaneous

XI.ac Thermal skin/dermal injury

XI. Miscellaneous

XI.ay Chest tightness

XI. Miscellaneous

XI.bc Polycythemia

XI. Miscellaneous

XI.bd Nicotine poisoning

XI. Miscellaneous

XI.be Burns

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.l Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.ag Bradycardia

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.a Methemoglobinemia

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XV. Pathology

XV.e Path: ILD with a granulomatous component (see also Im)

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.g Path: Alveolar hemorrhage (see also IIIa)

XV. Pathology

XV.p Path: Exogenous lipoid pneumonia

XV. Pathology

XV.x Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XV. Pathology

XV.y Path: Respiratory bronchiolitis (w/wo the RB-ILD-pattern)

XV. Pathology

XV.ab Path: Pulmonary capillaritis

XV. Pathology

XV.ba Path: Granulomatous lymphadenopathy

XV. Pathology

XV.bi Path: Giant-cell interstitial pneumonia (GIP)-pattern

XVI. Imaging

XVI.a Imaging: Diffuse haze

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.d Imaging: Alveolar opacities or haze with a batwing or butterfly distribution

XVI. Imaging

XVI.g Imaging: Diffuse whiteout/alveolar shadowing (see also under IIb-ARDS)

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.af Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.ai Imaging: A 'tree-in-bud' pattern

XVI. Imaging

XVI.bl Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

XVII. Infections & related conditions

XVII.a Respiratory tract infection incl. pneumonia

XVII. Infections & related conditions

XVII.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XVII. Infections & related conditions

XVII.h Nontuberculous pulmonary mycobacterial infection/superinfection

XVII. Infections & related conditions

XVII.ac Actinomycosis

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.x Eye catcher: A batwing pattern on imaging

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.b BAL: An excess proportion of neutrophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.c BAL: An excess proportion of eosinophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.d BAL: Gross or microscopic bleeding/hemorrhage

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.f BAL: Foamy macrophages

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.i BAL: Oil red O-stainable material in BAL macrophages othen than exogenous lipids

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.n BAL: Brown-pigmented macrophages

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.u Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.x Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.aq Interstitial Pneumonitis with Autoimmune Features (IPAF)

I. Interstitial/parenchymal lung disease

I.ar The association of ILD and myositis

IV. Airway involvement

IV.d Cough (lone)

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.b Eosinophilic pleural effusion

V. Pleural and/or pericardial involvement

V.d Pleural/pericardial effusion, ANA positive (DI lupus)

V. Pleural and/or pericardial involvement

V.h Chylothorax

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ac Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.ba Rhabdomyolysis (see also under Xj)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XII. Cardiovascular involvement / toxicity

XII.ab Pericardial fat necrosis

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XV. Pathology

XV.o Path: Endogenous lipoid pneumonia (phospholipidosis)

XV. Pathology

XV.ap Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

XV. Pathology

XV.co Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

XVI. Imaging

XVI.bx Imaging: Waxing and waning nodules

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.f BAL: Foamy macrophages